Literature DB >> 19582472

Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?

Sabine Biester, Focke Ziemssen, Karl Ulrich Bartz-Schmidt, Faik Gelisken.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582472     DOI: 10.1007/s00417-009-1132-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  8 in total

1.  Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

Authors:  Christos Haritoglou; Daniel Kook; Aljoscha Neubauer; Armin Wolf; Siegfried Priglinger; Rupert Strauss; Arnd Gandorfer; Michael Ulbig; Anselm Kampik
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

2.  Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Kumi Sakata; Hidetaka Noma; Tatsuya Mimura; Motohiro Suzuki; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

3.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

4.  Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema.

Authors:  R J Olk
Journal:  Ophthalmology       Date:  1986-07       Impact factor: 12.079

5.  Visual impairment in diabetes.

Authors:  R Klein; B E Klein; S E Moss
Journal:  Ophthalmology       Date:  1984-01       Impact factor: 12.079

6.  Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan G Sanchez; Jans Fromow-Guerra; Lihteh Wu; Maria H Berrocal; Michel E Farah; Jose Cardillo; Francisco J Rodríguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-03       Impact factor: 3.117

7.  Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.

Authors:  Roy W Beck; Allison R Edwards; Lloyd P Aiello; Neil M Bressler; Frederick Ferris; Adam R Glassman; Elizabeth Hartnett; Michael S Ip; Judy E Kim; Craig Kollman
Journal:  Arch Ophthalmol       Date:  2009-03

Review 8.  Diabetic macular edema: what is focal and what is diffuse?

Authors:  David J Browning; Michael M Altaweel; Neil M Bressler; Susan B Bressler; Ingrid U Scott
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

  8 in total
  3 in total

1.  A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy.

Authors:  Sampathkumar Rangasamy; Ramprasad Srinivasan; Joann Maestas; Paul G McGuire; Arup Das
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

Review 2.  [Diabetic maculopathy. Diagnosis and treatment].

Authors:  F Gelisken; F Ziemssen
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

3.  Intravitreal bevacizumab treatment for refractory diabetic macular edema.

Authors:  Erdem Yuksel; Sengul Ozdek; Nılay Yuksel; Berati Hasanreisoglu
Journal:  Int Ophthalmol       Date:  2013-03-19       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.